In a move that would advance its fight against tuberculosis (TB), the Modi Government has introduced the BPaLM regimen having composition of Bedaquiline, Pretomanid, Linezolid and Moxifloxacin (optional).
Talking about its need and benefits, a senior official from the Union Health Ministry said, it has a shorter treatment duration. “The BPaLM regimen offers a significant reduction in treatment time for Multi-Drug-Resistant Tuberculosis (MDR-TB) to six months, compared to the previous regimen which could extend up to 20 months,” he added.
It is proven to be safer and more effective, with a high success rate in curing drug-resistant TB. Also, it is cost effective. “The shorter duration and higher efficacy lead to overall cost savings. The regimen underwent thorough validation and health technology assessments to ensure safety and cost-effectiveness.”
The review was conducted by in-country experts and the Department of Health Research.
The official added that a nationwide roll-out plan is being developed by the Central TB Division in collaboration with States and UTs. This includes rigorous training for health professionals to ensure the safe administration of the new regimen.
This comprehensive approach is expected to significantly contribute towards India’s goal of ending TB by 2025 and sets a global benchmark for TB elimination efforts.
India has the world’s largest TB laboratory network with 7,767 rapid molecular testing facilities and 87 culture & drug susceptibility testing laboratories spread across the length & breadth of the country. This widespread laboratory network will support in timely detection of MDR-TB and quick initiation of TB treatment, the official added.
As per Soumya Swaminathan, principal advisor, National Tuberculosis Elimination Programme, “the move should improve treatment outcomes and help thousands of patients”.
Dr. Swaminathan early August had announced the plans in her post: “India is getting ready to roll out BPaL regimen for all M/XDRTB patients — training to begin this month. This should improve treatment outcomes & help thousands of patients. Scaling up NAAT coverage will be an essential element of the strategy.”
